angiotensin II

This medicine is authorised for use in the European Union.


Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock).

It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.

This EPAR was last updated on 10/10/2019

Authorisation details

Product details
Agency product number
Active substance
Angiotensin II acetate
International non-proprietary name (INN) or common name
angiotensin II
Therapeutic area (MeSH)
  • Hypotension
  • Shock
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
La Jolla Pharmaceutical II B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Herengracht 500
1017 CB Amsterdam

Product information

23/08/2019 Giapreza - EMEA/H/C/004930 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Assessment history

How useful was this page?

Add your rating